JC01 Rec'd PCT/PTO 01 JU 2005

CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Concise Statement of Relevance of Non-English References, Additional Information, Form PTO-1449 (1 Sheets), 1 Search Report, and 4 references are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

Date: [0]29/05

Attorney Docket No.: 101137-64

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Jacobus Thomas Wilhelumus Elisabeth Vogels

SERIAL NO. :

10/534,519

CUSTOMER NO.

27387

FILED

May 11, 2005

FOR

Detection of Demyelination

ART UNIT EXAMINER

TBA TBA

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO-1449 are being supplied.

Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

III. Concise Statement of Relevance

All references listed on the attached Form PTO-1449 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGIJŽIN & MARCUS, P.A.

Bv

Bruce S. Londa

Reg. No. 33,531

875 Third Avenue

18th Floor

New York, New York 10022

(212) 808-0700

LIST OF PATENTS AND PUBLICATIONS					Attorney Docket: 101137-64			Serial No.: 10/534,519		
APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Form PTO-1449)							Examiner: TBA Group: TBA			
Examiner's Initial		Document Number D		e Name		Class	Sub Class	Filing Date If appropriate		
	AA	6,181,134 B1	1/30/0	1 V	/ald	324	307	3/9/98		
		FORE	IGN PAT	ENT D	OCUMENTS					
		Document Number	Date	2	Country	Class	Sub Class	Trans Yes	lation No	
	AB	WO 98/41882	9/24/98		PCT	G01R	33/483			
	О	THER PRIOR ART (In	cluding A	uthor, '	Title, Date, Pert	inent Pag	es, Etc.)			
	AC	F. Giubilei, et al.; "Blood Cholesterol and MRI Activity in First Clinical Episode Suggestive of Multiple Sclerosis"; ACTA Neurologica Scandinavica; 2002; Volume 106; pages 109-112.								
	AD	M. N. Degaonkar; "Sequential Proton MRS Study of Brain Metabolite Changes Monitored During a Complete Pathological Cycle of Demyelination and Remyelination in a Lysophosphatidyl Choline (LPC)-induced Experimental Demyelinating Lesion Model"; NMR Biomedicine; 2002; Volume 15; Pages 293-300.								
	AE	A.G. Droogan, et al.; "Co Spin Echo Diffusion-We No. 5; Pages 653-661.	•							
EXAMINER:					DATE CONSIDERED:					